Neurocrine Biosciences
NBIX
NBIX
407 hedge funds and large institutions have $8.86B invested in Neurocrine Biosciences in 2021 Q2 according to their latest regulatory filings, with 48 funds opening new positions, 167 increasing their positions, 131 reducing their positions, and 54 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less capital invested
Capital invested by funds: $ → $
3% less funds holding
Funds holding: 418 → 407 (-11)
4.59% less ownership
Funds ownership: 101.27% → 96.68% (-4.6%)
11% less first-time investments, than exits
New positions opened: 48 | Existing positions closed: 54
Holders
407
Holding in Top 10
5
Calls
$83.8M
Puts
$54.6M
Top Buyers
| 1 | +$39.9M | |
| 2 | +$37.4M | |
| 3 | +$36.9M | |
| 4 |
Morgan Stanley
New York
|
+$22.9M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$19.5M |
Top Sellers
| 1 | -$275M | |
| 2 | -$81.6M | |
| 3 | -$71.3M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$44.8M |
| 5 |
Capital International Investors
Los Angeles,
California
|
-$43.7M |